INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Indivior PLC Investors (INVVY)

BENSALEM, Pa.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24INVVY&src=ctag” target=”_blank”gt;$INVVYlt;/agt; lt;a href=”https://twitter.com/hashtag/classaction?src=hash” target=”_blank”gt;#classactionlt;/agt;–Law Offices of Howard G. Smith announces that a class action lawsuit has
been filed on behalf of investors who purchased Indivior PLC (“Indivior”
or the “Company”) (OTC: INVVY)
securities between March 10, 2015 and April 9, 2019, inclusive
(the “Class Period”). Indivior investors have until June 24,
2019 to file a lead plaintiff motion.

Investors suffering losses on their Indivior investments are encouraged
to contact the Law Offices of Howard G. Smith to discuss their legal
rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that
a federal grand jury had indicted Indivior “for engaging in an illicit
nationwide scheme to increase prescriptions of Suboxone Film, an opioid
drug used in the treatment of opioid addiction.” According to the
indictment, Indivior deceived “health care providers and health care
benefit programs into believing that Suboxone Film was safer, less
divertible, and less abusable than other opioid-addiction treatment
drugs,” acquiring billions of dollars in revenue in Suboxone Film
prescriptions.

On this news, the Company’s share price fell $4.48 per share, more than
66%, to close at $2.30 per share on April 10, 2019, on unusually heavy
trading volume.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) Indivior and its
executives engaged in an illicit nationwide scheme to increase
prescriptions of Suboxone Film; (2) Indivior illegally obtained billions
of dollars in revenue from Suboxone Film prescriptions by deceiving
health care providers and health care benefit programs; (3) as a result,
Indivior would face felony charges; and (4) due to the foregoing,
defendants’ statements about its business, operations, and prospects,
were materially false and misleading and/or lacked a reasonable basis at
all relevant times.

If you purchased shares of Indivior, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by
telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com